

REMARKS

Claims 718-1110 are presently pending in this application. Claims 975 and 1029 have been amended. New claims 1111-1265 have been added. Accordingly, claims 718-1265 are being presented for further examination on the merits.

A new title has been substituted. The new title is believed to reflect more completely the subject matter of Applicants' claimed invention.

Minor errors in claims 975 and 1029 have been corrected above. In claim 975, the "solid support" in the preamble has been changed to -- composition -- ." By so doing, a proper antecedent basis has been restored to the claim. In claim 1029, an obvious error with respect to claim dependency has been corrected. As amended above, claim 1029 now properly depends from claim 1028.

Commensurate with Applicants' complete and broad disclosure, new claims 1111-1265 have been added above. Among these are new independent claims 1111 and 1193. Both are directed to a composition of matter comprising a plurality of substrate surfaces. In the case of claim 1111, the substrate surfaces comprise at least one double-stranded nucleic acid fixed or immobilized thereto, wherein at least one nucleic acid strand or a sequence therefrom comprises one or more non-radioactive chemical labels which comprise a non-radioactive signaling moiety or moieties which are quantifiable or detectable, and wherein at least one nucleic acid strand or a sequence therefrom in one of the substrate surfaces is different from at least one other nucleic acid strand or a sequence therefrom in another substrate surface. In the case of claim 1193, the substrate surfaces comprise at least one nucleic acid strand fixed or immobilized thereto, wherein at least one nucleic acid strand or a sequence therefrom in one of the substrate surfaces is different from at least one other nucleic acid strand or a sequence therefrom in another substrate surface.

Jannis G. Stavrianopoulos, et al.

Serial No.: 08/486,070

Filed: June 7, 1995

Page 23 [Supplemental Amendment to Applicants' March 7, 2001 Under 37 C.F.R.

§1.115 (In Response To The September 7, 2000 Office Action

- May 9, 2001]


SUMMARY AND CONCLUSIONS

Claims 1111-1265 have been added above. Claims 975 and 1029 have been amended. Accordingly, as amended and added above, claims 718-1265 are presented for further examination.

The fee for adding new claims 1111-1265 is \$10,386, based upon the large entity fee for 577 additional new claims above the 828 claims previously paid [577 claims X \$18 = \$10,386]. No independent claims have been added beyond the number of independent claims previously paid. As indicated in the accompanying Transmittal form, authorization is hereby given to charge the \$10,386 claim fee amount to Deposit Account No. 05-1135. No other fee or fees are believed due in connection with this filing. In the event that any other fee or fees are due, however, The Patent and Trademark Office is hereby authorized to charge the amount of any such fee or fees to Deposit Account No. 05-1135, or to credit any overpayment thereto.

If a telephone conversation would further the prosecution of the present application, Applicants' undersigned attorney request that he be contacted at the number provided below.

Respectfully submitted,



Ronald C. Fedus

Registration No. 32,567

Attorney for Applicants

ENZO DIAGNOSTICS, INC.
c/o ENZO BIOCHEM, INC.
527 Madison Avenue, 9th Floor
New York, New York 10022
Telephone: (212) 583-0100
Facsimile: (212) 583-0150